Sign in to follow this  
Followers 0
Joelf

Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome (SS): the BELISS open-label phase II study.

1 post in this topic

Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome (SS): the BELISS open-label phase II study.

 

Long–term treatment with belimumab may be beneficial in SS. PubMed, Rheumatology, 08/07/2015. (Also see Treatments for Symptoms of Sjögren's Syndrome)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde

ISN Assistant Webmaster

SD World Webmaster

ISN Sclero Forums Manager

ISN News Manager

ISN Hotline Support Specialist

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now
Sign in to follow this  
Followers 0